Loading organizations...
§ Public · Cambridge, MA, USA
Develops and commercializes precision therapies for cancer and hematologic disorders, targeting genetically defined diseases.
Blueprint Medicines is a Cambridge, Massachusetts-based biopharmaceutical company that develops precision therapies for patients with cancer and rare hematologic disorders. The firm focuses on targeting genetically defined diseases such as non-small cell lung cancer, generating revenue through the commercialization of its FDA-approved drug AYVAKIT and various strategic clinical development partnerships. Following an initial $40 million Series A financing round and a subsequent $147 million initial public offering, the company agreed to be acquired by Sanofi for a valuation of $9.5 billion in July 2025. Blueprint Medicines also maintains collaborative agreements with major pharmaceutical companies like Roche and reported $180.5 million in net product revenues during the 2023 fiscal year. The enterprise was originally founded in 2011 by investment firm Third Rock Ventures alongside scientific founders Nicholas Lydon, Brian Druker, Charles Sawyers, and Alexis Borisy.
Blueprint Medicines has raised $115.0M across 3 funding rounds.
Blueprint Medicines has raised $115.0M in total across 3 funding rounds.
Blueprint Medicines has raised $115.0M across 3 funding rounds. Most recently, it raised $50.0M Series C in November 2014.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Nov 12, 2014 | $50M Series C | Alex Virgilio | BVF Partners, Casdin Capital, Cowen Healthcare Investments, F Prime Capital, Nextech Invest, Perceptive Advisors, RA Capital Management, Redmile Group, Sabby Capital, Tavistock Group, Third Rock Ventures, Wellington Management | Announced |
| Jan 1, 2014 | $25M Series B | Thilo Schroeder | Flagship Ventures, F Prime Capital, GV, Nextech Invest, Third Rock Ventures, BVF Partners, Casdin Capital, F Prime Capital | Announced |
| Apr 1, 2011 | $40M Series A | Alexis A. Borisy | F Prime Capital | Announced |
Blueprint Medicines has raised $115.0M in total across 3 funding rounds.
Blueprint Medicines's investors include Alex Virgilio, BVF Partners, Casdin Capital, Cowen Healthcare Investments, F-Prime Capital, Nextech Invest, Perceptive Advisors, RA Capital Management, Redmile Group, Sabby Capital, Tavistock Group, Third Rock Ventures.
Blueprint Medicines is a global, fully integrated biopharmaceutical company, now a Sanofi company, that develops precision therapies targeting root causes of disease in allergy/inflammation and oncology/hematology.[1][2][3] It builds innovative kinase inhibitors and other modalities, such as AYVAKIT®/AYVAKYT® (avapritinib) for systemic mastocytosis (SM) and gastrointestinal stromal tumor (GIST), serving patients with mast cell disorders, allergic diseases, and cancers like PDGFRA-driven GIST and HR+/HER2- breast cancer.[2][4] The company solves unmet needs in serious diseases by addressing genetic drivers like KIT D816V mutations and mast cell activation, with strong growth from commercial launches, pipeline expansion (e.g., elenestinib, BLU-808), and 2025 proof-of-concept studies in chronic urticaria, allergic asthma, and more.[1][4]
Leveraging a scalable platform, Blueprint has two approved medicines and advances a diverse pipeline from discovery to late-stage development, emphasizing operational efficiency and a high-performing commercial engine.[1][2]
Founded in 2011 on the belief that innovative medicine development could be accelerated through a proprietary scientific platform, Blueprint Medicines rapidly progressed from discovery to global approvals for two breakthrough therapies within a decade.[3][5] Key early figures include scientists with expertise from institutions like Dana-Farber Cancer Institute, where researchers identified mutations like MYD88 L265P in Waldenström's macroglobulinemia (WM) and advanced kinase-targeting drugs, inspiring their move to Blueprint for mast cell diseases.[3]
The idea emerged from merging bioinformatics, structural biology, and drug design to target disease root causes, leading to pivotal moments like AYVAKIT's FDA approval for indolent SM in 2023 (two years celebrated in 2025) and expansions into Europe.[2][5] Acquisition by Sanofi enhanced its infrastructure, enabling broader pipeline scaling.[2]
Blueprint rides the precision medicine trend in biopharma, targeting genomic alterations and mast cell biology amid rising demand for therapies in rare/genetic diseases like SM and common allergic conditions.[1][3][6] Timing aligns with maturing kinase inhibitor tech and mast cell science, fueled by market forces like unmet needs in chronic urticaria (affecting millions) and oncology (e.g., PDGFRA GIST, CDK2 in breast cancer), plus post-approval expansions via partners like CStone in Greater China.[4]
It influences the ecosystem by pioneering scalable innovation from rare diseases (e.g., ISM approvals) to broader allergy/inflammation, shifting treatment paradigms through integrated capabilities and thought leadership like the PROSPECTOR Study on mast cell activation.[1][5]
Blueprint's 2025 priorities include advancing BLU-808 proof-of-concept across urticaria, asthma, rhinitis, and mast cell syndromes, elenestinib commercialization, and CDK2 degrader progress, positioning it for franchise expansion in mast cells and oncology.[1] Trends like AI-enhanced discovery and allergy market growth will shape its path, potentially evolving from niche precision player to broad therapeutic leader via Sanofi's scale. This builds on its decade-long track record, fundamentally improving lives by targeting disease origins.[2][3]